Regarding the negative results for concordance between adjuvant iCDK criteria and genomic risk, Sheffield et al [3] correlated each of the MonarchE clinical criteria (lymph node involvement, histological grade, tumour size >5 cm, and Ki-67 >20%) in a phase III study and evaluated invasive disease-free survival and distant recurrence-free survival in early HR+ HER2-negative breast cancer patients. The gene discussed is ERBB2; the disease is breast cancer.